In conclusion, half of our patients with NSCLC had PD‐L1 expression determined and the prevalences of PD‐L1 TPS ≥50%, 1–49%, and <1% were 28.2%, 32.3%, and 39.5%, respectively. This evidence concerns the gene CD274 and non-small cell lung carcinoma.